Table 1. Demographic Characteristics.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Savolitinib, 600 mg (n = 33) | Sunitinib, 50 mg (n = 27) | Total (n = 60) | |
| Age, median (range), y | 60 (23-78) | 65 (31-77) | 62 (23-78) |
| Sex | |||
| Male | 29 (88) | 17 (63) | 46 (77) |
| Female | 4 (12) | 10 (37) | 14 (23) |
| Race | |||
| White | 29 (88) | 23 (85) | 52 (87) |
| Black | 1 (3) | 1 (4) | 2 (3) |
| Asian | 2 (6) | 3 (11) | 5 (8) |
| Other | 1 (3) | 0 | 1 (2) |
| Countrya | |||
| France | 1 (3) | 0 | 1 (2) |
| Italy | 2 (6) | 3 (11) | 5 (8) |
| Russia | 7 (21) | 9 (33) | 16 (27) |
| Ukraine | 12 (36) | 5 (19) | 17 (28) |
| South Korea | 2 (6) | 3 (11) | 5 (8) |
| United States | 3 (9) | 0 | 3 (5) |
| Brazil | 6 (18) | 7 (26) | 13 (22) |
| IMDC risk group | |||
| Poor | 4 (12) | 3 (11) | 7 (12) |
| Intermediate | 22 (67) | 17 (63) | 39 (65) |
| Favorable | 7 (21) | 7 (26) | 14 (23) |
| Line of therapy | |||
| 1st line | 28 (85) | 25 (93) | 53 (88) |
| ≥2nd line with prior VEGF-TKI | 3 (9) | 0 | 3 (5) |
| ≥2nd line without prior VEGF-TKI | 2 (6) | 2 (7) | 4 (7) |
| Histology subtype | |||
| Type 1 | 10 (30) | 7 (26) | 17 (28) |
| Type 2 | 11 (33) | 10 (37) | 21 (35) |
| Unspecified | 10 (30) | 10 (37) | 20 (33) |
| Missing | 2 (6) | 0 | 2 (3) |
| Karnofsky performance status | |||
| 100% | 11 (33) | 4 (15) | 15 (25) |
| 90% | 15 (45) | 16 (59) | 31 (52) |
| 80% | 7 (21) | 7 (26) | 14 (23) |
| SAVOIR CTA-specific MET-driven (BICR)b | |||
| MET amplification | 1 (3) | 1 (4) | 2 (3) |
| HGF amplification | 1 (3) | 0 | 1 (2) |
| MET variation | 2 (6) | 3 (11) | 5 (8.3) |
| Chromosome 7 gain | 30 (91) | 26 (96) | 56 (93) |
Abbreviations: BICR, blinded independent central review; CTA, clinical trial assay; HGF, hepatocyte growth factor; IMDC, Independent Data Monitoring Committee; VEGF-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.
a
Patients were enrolled in 57 study centers, and of these, 32 study centers had patients randomized.
b
Patients can be counted in more than 1 subtype group for MET driven by SAVOIR CTA.